PLX/ 10/17/2025 · 9:38 AM Elfabrio Every-4-Weeks Dosing Rejected by EMA Committee Chiesi and Protalix received a negative CHMP opinion for Elfabrio's dosing regimen. The companies remain committed to reducing the treatment burden for Fabry disease patients.